AKTRES study: A Biologic Study of the early effects and determinants of AKT inhibition using GSK2110183 alongside chemotherapy in patients with Platinum RESistant Adenocarcinoma of the ovary

Trial Profile

AKTRES study: A Biologic Study of the early effects and determinants of AKT inhibition using GSK2110183 alongside chemotherapy in patients with Platinum RESistant Adenocarcinoma of the ovary

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs Afuresertib (Primary) ; Carboplatin; Paclitaxel
  • Indications Ovarian cancer
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms AKTRES
  • Most Recent Events

    • 05 Dec 2014 Accrual to date is 66% according to United Kingdom Clinical Research Network record.
    • 06 Mar 2014 Accrual to date is 50% according to United Kingdom Clinical Research Network record.
    • 07 Feb 2014 Accrual to date is 45% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top